Hybrid stochastic framework predicts efficacy of prophylaxis against HIV: An example with different dolutegravir prophylaxis schemes
Table 2
Pharmacokinetic parameter estimates.
The table displays the estimated pharmacokinetic parameter estimates for healthy individuals. Interindiviual variability (random effects) was included on drug clearance CL/Fbio and the volume of distribution Vc/Fbio. These parameters were log-normal distributed as outlined in the Methods section, eq (11), with coefficient of variation [%] , where σ2 is the variance of the associated normal distribution. A covariance of
between x = CL/Fbio and y = Vc/Fbio was estimated. The absorption rate constant was fixed [88] to 2.24h−1. Residual variability (eq (10)) was described by a combined proportional-additive model for healthy volunteers [σ = 0.213 (37.2%) and
0.0019 mg/L (40.9%), respectively] and a proportional error model for HIV-infected patients [σ = 0.402 (24.2%)].